Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Resolution of organ fibrosis
Joon-Il Jun, Lester F. Lau
Joon-Il Jun, Lester F. Lau
Published January 2, 2018
Citation Information: J Clin Invest. 2018;128(1):97-107. https://doi.org/10.1172/JCI93563.
View: Text | PDF
Review Series

Resolution of organ fibrosis

  • Text
  • PDF
Abstract

Fibrosis is the excessive accumulation of extracellular matrix that often occurs as a wound healing response to repeated or chronic tissue injury, and may lead to the disruption of organ architecture and loss of function. Although fibrosis was previously thought to be irreversible, recent evidence indicates that certain circumstances permit the resolution of fibrosis when the underlying causes of injury are eradicated. The mechanism of fibrosis resolution encompasses degradation of the fibrotic extracellular matrix as well as elimination of fibrogenic myofibroblasts through their adaptation of various cell fates, including apoptosis, senescence, dedifferentiation, and reprogramming. In this Review, we discuss the present knowledge and gaps in our understanding of how matrix degradation is regulated and how myofibroblast cell fates can be manipulated, areas that may identify potential therapeutic approaches for fibrosis.

Authors

Joon-Il Jun, Lester F. Lau

×

Figure 1

Transdifferentiation of precursor cells into fibrogenic myofibroblasts.

Options: View larger image (or click on image) Download as PowerPoint
Transdifferentiation of precursor cells into fibrogenic myofibroblasts.
...
Upon parenchymal injury, the wound-healing response leads to the release of fibrogenic growth factors and cytokines, the most prominent of which is TGF-β1. These factors drive the transdifferentiation and proliferation of precursor cells into myofibroblasts. Major precursors of myofibroblasts are cells of mesenchymal origin, including resident fibroblasts, pericytes, and Gli+ mesenchymal stem cell–like (MSC-like) cells. In some cases, myofibroblasts may be derived from bone marrow–derived (BM-derived) fibrocytes or through mesothelial-to-mesenchymal transition (MMT). Myofibroblasts produce ECM comprising fibrillar collagens that undergo extensive cross-linking and EDA-fibronectin, which promotes TGF-β1–induced transdifferentiation.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts